Italian startup DeepTrace Technologies announced its first investment round to support the company's growth and further develop its artificial intelligence (AI) software for medical imaging.
The company's software automatically predicts the probability of clinically significant disease onset, progression, and good or poor therapy response. The company's goal is to develop software to estimate the risk of cardiovascular disease or poor outcome after surgical treatment, the risk of malignant breast lesions, and the risk of Alzheimer's disease.
The initial seed funding round was led by Progress Tech Transfer, with the strategic advisor MITO Technology.
DeepTrace Technologies' AI tools have been adopted by Italian research institutes and DeepTrace wants to expand its customer base not only in Europe but also in North America and Asia.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
